Literature DB >> 21067391

Sipuleucel-T immunotherapy for castration-resistant prostate cancer.

Chadi Nabhan.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21067391     DOI: 10.1056/NEJMc1009982

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  5 in total

Review 1.  Immunotherapy for the treatment of prostate cancer.

Authors:  Giuseppe Di Lorenzo; Carlo Buonerba; Philip W Kantoff
Journal:  Nat Rev Clin Oncol       Date:  2011-05-24       Impact factor: 66.675

Review 2.  Therapeutic Vaccines Targeting Neoantigens to Induce T-Cell Immunity against Cancers.

Authors:  Shih-Cheng Pao; Mu-Tzu Chu; Shuen-Iu Hung
Journal:  Pharmaceutics       Date:  2022-04-15       Impact factor: 6.525

3.  Enhancing Cell therapies from the Outside In: Cell Surface Engineering Using Synthetic Nanomaterials.

Authors:  Matthias T Stephan; Darrell J Irvine
Journal:  Nano Today       Date:  2011-06-01       Impact factor: 20.722

4.  Audencel Immunotherapy Based on Dendritic Cells Has No Effect on Overall and Progression-Free Survival in Newly Diagnosed Glioblastoma: A Phase II Randomized Trial.

Authors:  Johanna Buchroithner; Friedrich Erhart; Josef Pichler; Georg Widhalm; Matthias Preusser; Günther Stockhammer; Martha Nowosielski; Sarah Iglseder; Christian F Freyschlag; Stefan Oberndorfer; Karin Bordihn; Gord von Campe; Markus Hoffermann; Reinhard Ruckser; Karl Rössler; Sabine Spiegl-Kreinecker; Michael B Fischer; Thomas Czech; Carmen Visus; Günther Krumpl; Thomas Felzmann; Christine Marosi
Journal:  Cancers (Basel)       Date:  2018-10-05       Impact factor: 6.639

5.  miR‑367‑3p downregulates Rab23 expression and inhibits Hedgehog signaling resulting in the inhibition of the proliferation, migration, and invasion of prostate cancer cells.

Authors:  Wei Du; Dong Li; Jianhao Xie; Ping Tang
Journal:  Oncol Rep       Date:  2021-07-19       Impact factor: 3.906

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.